Longeveron Inc. (LGVN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Longeveron reported revenue of $1.2M, down 49.9% from $2.4M the year before. Net income was -$22.7M (a -1893.6% net margin), or -$12.90 per diluted share. Gross margin was 67.0% and operating margin was -1942.2%. Operating activities generated -$18.6M of cash, leaving -$18.9M of free cash flow. At fiscal year end, Longeveron held $10.3M in total assets against $4.6M in total liabilities, including $4.7M of cash and equivalents.
Open the full interactive Longeveron financials → Quarterly statements, key ratios, valuation history and price charts.
Longeveron Key Stats
| Share Price | $2.15 |
|---|---|
| Market Cap | $6.7M |
| Revenue YoY Growth | -49.9% |
| 52-Week Range | $2.15 – $11.60 |
| Shares Outstanding | 3.1 million (basic, 2026 Q2) |
Longeveron Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $1.2M | $709,000 | $2.4M | $1.2M |
| Gross Profit | $590,000 | $497,000 | $221,000 | $1.9M | $803,000 |
| Operating Income | -$17.5M | -$18.0M | -$21.0M | -$16.5M | -$23.3M |
| Pre-Tax Income | -$17.0M | -$18.8M | -$21.4M | -$16.0M | -$22.7M |
| Income Tax | — | — | $0 | $0 | $0 |
| Net Income | -$17.0M | -$18.8M | -$21.4M | -$16.0M | -$22.7M |
| Diluted EPS | -$90.00 | -$90.00 | -$102.00 | -$26.20 | -$12.90 |
Longeveron Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $137,000 | $365,000 | $398,000 | $287,000 |
| Net Income | -$7.2M | -$5.4M | -$4.7M | -$6.1M |
| Diluted EPS | -$3.90 | -$0.31 | -$1.90 | -$1.90 |
Longeveron Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $25.7M | $10.5M | $4.9M | $19.2M | $4.7M |
| Current Assets | $35.4M | $20.3M | $5.8M | $19.6M | $5.5M |
| Total Assets | $42.8M | $27.4M | $12.1M | $25.6M | $10.3M |
| Current Liabilities | $2.7M | $4.9M | $3.9M | $2.6M | $4.1M |
| Total Long-Term Debt | $2.6M | $2.0M | — | — | — |
| Total Liabilities | $5.3M | $6.9M | $5.3M | $3.7M | $4.6M |
| Shareholders' Equity | $37.5M | $20.5M | $6.7M | $21.9M | $5.7M |
Longeveron Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$9.6M | -$14.0M | -$19.0M | -$13.9M | -$18.6M |
| Cash From Investing | -$10.7M | -$677,000 | $8.2M | -$640,000 | -$595,000 |
| Cash From Financing | $45.2M | -$509,000 | $5.3M | $28.8M | $4.7M |
| Free Cash Flow | -$10.0M | -$14.5M | -$19.3M | -$14.5M | -$18.9M |
Figures from Longeveron's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Longeveron financials page for every line item.
Longeveron Company Profile
| Ticker | LGVN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Miami, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001721484 |
Frequently Asked Questions
What was Longeveron's revenue in fiscal 2025?
Longeveron (LGVN) reported revenue of $1.2M for fiscal 2025.
What is Longeveron's annual revenue history?
Longeveron's annual revenue by fiscal year: 2021: $1.3M; 2022: $1.2M; 2023: $709,000; 2024: $2.4M; 2025: $1.2M.
What was Longeveron's net income in fiscal 2025?
Longeveron reported net income of -$22.7M for fiscal 2025.
What was Longeveron's earnings per share (EPS) in fiscal 2025?
Longeveron's diluted EPS was -$12.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Longeveron generate in fiscal 2025?
Longeveron generated -$18.9M of free cash flow in fiscal 2025.
What was Longeveron's revenue last quarter?
In its most recent reported quarter (2026 Q2), Longeveron reported revenue of $287,000.
How many shares of Longeveron are outstanding?
Longeveron reported a weighted average of 3.1 million basic shares outstanding in 2026 Q2.
What is Longeveron's market cap?
Based on its latest closing price, Longeveron (LGVN) has a market capitalization of about $6.7M.
When does Longeveron's fiscal year end?
Longeveron's fiscal year end, as registered with the SEC, is December 31.
Where is Longeveron headquartered?
Longeveron lists its business address in Miami, Florida in its SEC filings.